A phase 1/2 open-label study to assess the safety, tolerability, and pharmacokinetics of intravenous infusion of MB07133 [Metabasis Therapeutics] in subjects with unresectable hepatocellular carcinoma and Child-Pugh Class A liver function
Latest Information Update: 03 Nov 2021
At a glance
- Drugs MB 7133 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Metabasis Therapeutics
- 17 Apr 2007 Status changed from in progress to completed
- 12 Sep 2005 New trial record.